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Summary.-Thirty-two adults with acute myeloid leukaemia (AML) were random-
ized to receive, from the time of diagnosis, either chemotherapy alone (C group) or
chemotherapy plus Bacille Calmette-Guerin vaccine (BCG) (C+I group). After
remission induction and consolidation, chemotherapy was stopped in both groups
but BCG was continued in the C+ I group.
The overall survival of the C+I group was significantly increased (P <0-05). There
was no significant increase in the duration of first remission in the C+I group
(0 05 <P<0.1) nor in the time from first relapse to death (0.05 <P<0.1). There was
no significant difference in the incidence of first or second remissions, and the time
taken to enter remission did not differ significantly between the two groups. Com-
parison with the results of other trials suggests that the use of maintenance chemo-
therapy in addition to immunotherapy produces longer remissions.
Five patients in the C group developed leukaemic central-nervous-system (CNS)
involvement, in comparison with none in the C+ I group. CNS relapse did not produce
a significant decrease in remission length (P>0.1) but reduction in survival after
CNS relapse was highly significant (P=0 001). These results suggest that adminis-
tration of BCG from an early stage in the treatment of AML may protect the CNS
against leukaemic infiltration and therefore serve as a simple, innocuous form of
CNS prophylaxis.
SINCE Powles et al. (1973) reported on
the efficacy ofusing immunotherapy in the
treatment ofAML, other studies have been
carried out using BCG alone (Gutterman
et al., 1974; Vogler & Chan, 1974; Whit-
taker & Slater, 1977; Vuvan et al., 1978),
BCG plus leukaemic cells (Freeman et al.,
1973; M.R.C., 1.978), or leukaemic cells
alone (Bekesi et al., 1977; Ezaki et al.,
1978). The results of 6 randomized trials
of immunotherapy in AML were reviewed
at a meeting of the National Cancer
Institute in October 1976 (NCI, 1977;
MRC, 1978). It was concluded that
immunotherapy probably does prolong
survival after relapse and possibly extends
the duration of first remission.
Previous studies were based on the
premise that immunotherapy is best given
when the tumour cell mass is low (Mathe,
1969; Mathe et al., 1969) and therefore this
treatment was not started until after
remission had been attained.
The aim of this trial was to determine
the effect of BCG given regularly from the
time ofdiagnosis ofAML and continued as
the sole form of maintenance therapy
after remission induction and consolida-
tion. Neither of these methods of using
BCG has previously been assessed.
PATIENTS AND METHODS
Between October 1975 and July 1977, 32
adults wvith acute non-lymphoblastic leu-
kaemia were entered into the trial. There were
17 males and 15 females, and their ages
ranged from 18 to 65 (mean 48) years. The
trial was concluded on 1 March 1979.
Address for correspondence: Dr G. P. Summerfield, Department of Haematology, 3rd Floor, Duncan
Building, Royal Liverpool Hospital, Lixverpool L7 8XW.G. P. SUMMERFIELD, T. J. GIBBS AND A. J. BELLINGHAM
Diagnosis. On the basis of marrow cyto-
logy and cytochemical staining techniques
(Hayhoe et al., 1964) 24 patients had acute
myeloblastic leukaemia, 2 had acute pro-
myelocytic leukaemia and 6 had acute
myelo-monocytic leukaemia.
Randomization.-Using Medical Research
Council criteria (MRC, 1975) the 32 patients
were prospectively stratified into 2 groups
with either good or poor prognosis. Each of
these groups was further subdivided using
previously selected random numbers. On
recombining these subgroups, two major
groups were created with comparable prog-
nostic features, one to receive chemotherapy
and BCG (C+I group, 14 patients), the
other chemotherapy alone (C group, 18
patients).
Induction.-This consisted of Barts Trial
No. 3 chemotherapy (Crowther et al., 1973)
using daunorubicin and cytosine arabinoside.
Remisston. - Complete remission was
judged to have occurred when a cellular
marrow was obtained with less than 5%
blast cells.
Consolidation.-This consisted of a 6-week
course of continuous oral thioguanine and 6
injections of i.v. cyclophosphamide at weekly
intervals (Freeman et al., 1973) starting
immediately after the remission marrow had
been obtained.
Maintenance.-No further chemotherapy
was given after the completion of the con-
solidation course.
Immunotherapy.-Glaxo freeze-dried BCG
vaccine was given weekly by the intradermal
route at a dose of 106 viable organisms, using
a 20-needle multiple puncture Heaf gun. This
was fired twice into one limb, each limb being
used successively in a 4-week rotation.
The incidence of secondary sepsis and
haemorrhage at the site of administration
was low, and no systemic effects were
apparent. Postmortem examinations on
patients who had received BCG showed no
evidence of systemic BCG disease.
All patients were seen weekly for clinical
assessment and peripheral-blood counts,
whether or not they were receiving BCG. If
any abnormality was detected which sug-
gested relapse, a sternal marrow aspirate was
performed immediately. Otherwise, marrow
specimens were obtained at monthly intervals
in all patients. This was of particular import-
ance since no maintenance chemotherapy was
being given.
Where possible postmortem examinations
were performed on all patients.
The monthly marrows and postmortem
material from patients in the BCG group
were routinely cultured for M. tuberculosis
and BCG.
Reinduction.-This was attempted by fur-
ther administration of daunorubicin and
cytosine arabinoside, provided that a total
dose of 800 mg of daunorubicin had not been
exceeded. If this was not successful, cytosine
arabinoside was given in combination with
oral thioguanine.
CNS relapse.-Diagnosis of CNS involve-
ment was made on clinical features and ex-
amination of cerebrospinal fluid (CSF) re-
moved by standard lumbar puncture. Smears
of' CSF samples were processed in the
Shandon cytocentrifuge (Drewinko et al.,
1973) and stained with Wright's stain. CNS
leukaemia was treated with intrathecal
cytosine arabinoside, and also in one patient
by administration of the drug via an im-
planted Omaya reservoir.
Statistical methods. - The data were
analysed using Kaplan-Meier life-tables and
logrank P values as described previously for
the analysis of randomized clinical trials
requiring prolonged observation of each
patient (Peto et al., 1976, 1977); P values for
the incidence of first and second remissions
were calculated by Fisher's exact test.
RESULTS
The results are summarized in Tables I,
II & III.
There were 8 first remissions out of 14
patients (57%) in the C+I group and 7
out of 18 patients (39%) in the C group.
There were 2 second remissions out of 8
patients in the C +I group (25%) and 1
out of 7 patients in the C group (14%).
Neither of these differences in remission
rate is statistically significant (P> 0.5).
The life-table estimate of the prob-
ability of survival after randomization in
the two therapeutic groups is shown by
Fig. 1. The difference in overall survival
between the groups is statistically sig-
nificant (x2 = 4-52, P < 0.05) when analysed
by the logrank test. Two patients in the
C +I group remain alive, well and in
remission at the end of the trial.
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TABL:
No. ofpatients
No. of 1st
remissions
No. of2nd
remissions
Median overall
survival
(days)
Median length oi
1st remission
(days)
Median time to
enter remissio
(days)
Median survival
from 1st
relapse (days)
Incidence of
CNS
involvement
E I.-Summary ofdata The life-table estimate of the prob-
Chemo- ability of survival in complete remission
therapy Chemo- is shown by Fig. 2. The increased duration +BCG therapy of first remission in the C+I group (C+I) (C) P narrowly failed to achieve statistical sig-
14 18 nificance (X2=3.55, 0-05 <P < 0 1).
8 (57%) 7 (39%) 0.50 The life-table estimate ofthe probability of survival after the first relapse is shown
2 (25%) 1 (14%) >050 by Fig. 3. Although survival from relapse
to death was greater in the C+I group,
388 171 <0 05 this difference was not statistically sig- (2 patients x2=4*52 nificant (X2= 3-00, 0-05 <P < 0.1). still alive) Ofthe 7 patients in the Cgroup entering
f remission, 5 developed CNS leukaemia
172 131 >005<0.1 whilst in remission. The length of remis- x2= 355 sion of the 15 patients entering remission
was not significantly decreased by CNS
90 56 >o l relapse (X2= 1 79 P>0 1) but the reduc- x2=0-69 tion in survival after CNS relapse was
highly significant (x2= 10-83, P=0.001).
182 27 >0.05<0.1 The presenting clinical features of CNS (6patients) X2=300 relapse are shown in Table IV. In each
case malignant cells were found in the
0 (0%) 5 (71%) See text CSF by the cytocentrifuge technique.
TABLE II.-Chemotherapy group (18 patients, C)
Patient
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
Diagnosis
AML
AML
APML
AML
AML
AML
AML
AML
AML
AMML
AML
AML
AML
AML
AML
AML
AML
AML
Overall
survival
(days)
235
198
85
185
118
71
42
13
29
8
11
406
340
375
154
244
187
511
Remission
No
No
No
No
No
No
No
No
No
No
No
Yes
Yes
Yes
Yes
Yes
Yes
Yes*
Time to
enter
remission
(days)
123
56
129
42
54
51
78
Length of
remission
(days)
85 (70)t
131
236 (166)
104 (103)
163 (158)
125 (124)
143
Time
from 1st
relapse
to death
(days)
198 (213)4
153
10 (80)
8 (9)
27 (32)
11 (12)
290
* This patient also achieved a 2nd remission.
t Figures in parentheses denote time to CNS relapse. t Figures in parentheses denote time from CNS relapse to death.
AML=Acute myeloblastic leukaemia.
AMML=Acute myelomonocytic leukaemia.
APML =Acute promyelocytic leukaemia.
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TABLE III. Chemotherapy plus BCG group (14 patients, C+I)
Patient
1
2
3
4
5
6
7
8
9
10
11
12
13
14
Diagnosis
A'MMIL
AINIIL
AMINIL
AMIML
AALML
AMIL
ANIL
AML
AMIL
AML
AMlL
AML
ANIL
APAIL
Overall
surviv-al
(days)
22
576
425
433
427
612
767
159
55
19
24
569
350
52
Remission
No
Yes
Yes
Yes
Yes
Yes*
Yes*
No
No
No
No
Yes
Yes
No
* Patients also achieving a 2nd remission.
Abbreviations as in Table Il.
TABLE IV. Mode of presentation of COAlS
involvement (C Group only)
Patient
No.
12
14
15
16
17
Fronto-occipital headaches, bitemporal
pallor ofdiscs
Scotoma in left visual field, cranial nerve
palsies
Frontal headachles, (liplopia, papilloedlema
Fronto-occipital lhea(laclhes, papilloelema
Bizarre confusional state
Marrow relapse was diagnosed following
CNS relapse within 1, 1, 5, 15 and 70 days
in the 5 affected patients (see Table II and
Figs. 2 and 3). Survival from the develop-
ment of CNS relapse in these patients was
9, 11, 32, 213 and 80 days respectively.
CNS involvement was therefore generally
associated with early marrow relapse and
with reduction of survival from the time
of marrow relapse.
DISCUSSION
This is the first trial to use BCG as the
sole form of immunotherapy in AML
starting from the time of diagnosis. It is
also unique in that BCG was given as the
only remission maintenance in one group,
while the other group had no active main-
tenance therapy. Neither group received
maintenance chemotherapy. The chemo-
therapy used in this trial was based on
50
Time to
enter
remission
((lays)
88
139
78
92
104
58
Lengtlh of
remission
(dlays)
162
126
182
146
429
252
Time
from 1st
relapse
to (leathi
(days)
326
160
173
191
79+
457+
47 259 263
126 144 80
that devised 8 years ago (Crowther et al.,
1973) and the results are comparable with
those obtained at that time, although the
results of both groups may be worse than
those in more recent studies.
Previous trials of immunotherapy in
AML have shown that it can probably
prolong survival after relapse, and possibly
slightly extend first remission (NCI, 1977).
Although in this trial there was a sig-
nificant increase in overall survival in the
C+I group, the length of first remission
was not significantly increased and, al-
though we found increased survival follow-
ing relapse, this again was not statistically
significant. The MRC in its final report on
immunotherapy trials in AML raised two
questions which still need to be answered:
"Does immunotherapy prolong first re-
mission?" and "Does immunotherapy pro-
long survival after relapse?" Unfortu-
nately, the small number ofpatients inthis
trial prevents us from drawing any firm
conclusions which might help to provide a
definite answer to these questions.
The time taken for patients to achieve
first remission was longer in the C+ I
group, but the difference from the C group
was not significant (x2=0 69, P>0-1).
BCG therefore did not appear to decrease
the remission induction period.
The median remission length of our
C +I group is comparable to that of
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FiG. 1.-Life-table estimate of the probability of survival after randomization of 32 patients
allocated at random to receive either chemotherapy alone (C, 18 patients * *), or chemo-
therapy and BCG (C+I, 14 patients 0--- -0). Solid symbols-dead; open symbols-alive at end
oftrial period.
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FIG. 2.-Life-table estimate of the probability of survival in marrow remission of 15 patients who
received no active maintenance therapy (C, 7 patients * *) or BCG maintenance therapy
(C+I, 8 patients 0*-- 0). All patients relapsed during trial period. N: Patients with CNS relapse;
figures in parentheses are days from CNS relapse to marrow relapse.
patients treated with chemotherapy alone
in previous trials (Powles et al., 1973) (172
as against 188, 188 and 209 days). The
median remission length of our C +I group
is inferior to that of patients receiving
maintenance chemotherapy plus immuno-
therapy using BCG plus leukaemic cells
(172 as against 375, 312 and 371 days).
These results suggest that the use of
chemotherapy in addition to immuno-
therapy for maintenance does further in-
crease the length of remission. The failure
of our trial to show a significant pro-
longation of remission in the BCG group
does however suggest the alternative con-
clusion that the superior results of Powles
et al. were due to the addition ofleukaemic
cells to the immunotherapy regime. This
possibility is made less likely by the
favourable comparison of our results with
those of another group using BCG plus
irradiated allogeneic leukaemic cells (Free-
man et al., 1973). A direct comparison is
possible in this case with our trial,
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FIG. 3.-Life-table estimate of the probability ofsurvival after the first marrow relapse of 15 patients
who received either chemotherapy alone (C, 7 patients * *), or chemotherapy and BCG
(C +I, 8 patients 0--- 0). Solid symbols-dead, open symbols-alive at end of trial period.
N: Patients with CNS relapse. Figures in parentheses are days from CNS relapse to death.
because the induction chemotherapy was
identical and no maintenance chemo-
therapy was given, the only difference
between the trials being that we gave
BCG from the time of diagnosis and
Freeman et al. gave BCG and leukaemic
cells from the time of remission. Free-
man's group obtained a mean (not median)
remission length of 20 weeks, compared
with 30 weeks in our trial, suggesting that
BCG alone is as effective in maintaining
remission as BCG plus leukaemic cells.
The incidence of CNS relapse was very
much higher in our C group (71%) than in
the C+I group (0%O) and produced a
highly significant reduction in survival
compared with patients in both groups
who did not develop CNS relapse.
CNS involvement receives little atten-
tion in previous reports of the use of
immunotherapy in AML. There is experi-
mental evidence that immunotherapy
with i.v. Corynebacterium parvum causes
a slight but significant increase in the
survival of BALB/c mice injected intra-
cerebrally with methylcholanthrene-in-
duced sarcoma (Osborn et al., 1975). This
finding may be relevant to the apparent
protection of the CNS in our C+I group
from clinically overt leukaemic infiltra-
tion. None of the patients receiving BCG
suffered any complications from the treat-
ment, and therefore BCG may offer a
simple and harmless means of CNS
prophylaxis, in contrast with intrathecal
drugs (MRC, 1978) and cranial irradiation
(Dahl et al., 1978).
It would seem that further assessment
is warranted of the use of BCG in AML in
larger-scale trials in conjunction with more
recent and intensive forms of chemo-
therapy.
This work was supported by the North West
Cancer Research Fund and is part of an M.D. thesis
to be submitted by T. J. Gibbs to the University of
Liverpool.
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